GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » Graham Number

VIR (Vir Biotechnology) Graham Number : $N/A (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2025-04-14), the stock price of Vir Biotechnology is $5.53. Vir Biotechnology's graham number for the quarter that ended in Dec. 2024 was $N/A. Therefore, Vir Biotechnology's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Vir Biotechnology's Graham Number or its related term are showing as below:

During the past 8 years, the highest Price to Graham Number ratio of Vir Biotechnology was 1.58. The lowest was 0.65. And the median was 1.12.

VIR's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 1.9
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Vir Biotechnology Graham Number Historical Data

The historical data trend for Vir Biotechnology's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology Graham Number Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Graham Number
Get a 7-Day Free Trial - 26.51 38.79 - -

Vir Biotechnology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vir Biotechnology's Graham Number

For the Biotechnology subindustry, Vir Biotechnology's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vir Biotechnology's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's Price-to-Graham-Number falls into.


;
;

Vir Biotechnology Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Vir Biotechnology's Graham Number for the fiscal year that ended in Dec. 2024 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*8.217*-3.533)
=N/A

Vir Biotechnology's Graham Number for the quarter that ended in Dec. 2024 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*8.217*-3.55)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vir Biotechnology  (NAS:VIR) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Vir Biotechnology's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2024 )
=5.53/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Vir Biotechnology Graham Number Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Vir Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Executives
Ann M. Hanly officer: Chief Technology Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos director, officer: President and CEO C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Backer Marianne De officer: Chief Executive Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Janet Napolitano director C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Sung Lee officer: Chief Financial Officer 7000 MARINA BLVD, BRISBANE CA 94005
Phillip Pang officer: Chief Medical Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Svf Endurance (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Steven J. Rice officer: Chief Administrative Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Johanna Friedl-naderer officer: Chief Business Officer, Global C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Howard Horn officer: CFO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin officer: EVP, Research & CSO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001